Algernon Pharmac Stock Price, News & Analysis

Algernon Pharmaceuticals has launched a clinical research program for pancreatic cancer (PC) using NP-120 (Ifenprodil), which showed a 50% reduction in tumor size in a murine model. The five-year survival rate for PC is a stark 7.9%, prompting the company to investigate Ifenprodil’s potential further, given its historical safety record. The company plans to submit a pre-IND meeting request to the U.S. FDA and seeks orphan designation and Fast Track status for Ifenprodil. The global pancreatic cancer treatment market is projected to reach USD 4.2 billion by 2025.

Algernon Pharmaceuticals Inc. (CSE: AGN, OTCQB: AGNPF) announced an independent study from the University of Szeged showing that N,N-dimethyltryptamine (DMT) significantly reduces cell death in a rat stroke model. Published in Neuropharmacology, the study highlighted DMT's potential to decrease damaging biological processes following a stroke. Algernon aims to initiate a human clinical trial for DMT as a stroke treatment in Q4 2021 and has filed provisional patents for its use. CEO Christopher J. Moreau emphasizes DMT's potential in stroke therapy.

Algernon Pharmaceuticals (CSE: AGN) has received positive feedback from the FDA regarding its plans to investigate AP-188 (DMT) as an adjunct to physical therapy for stroke rehabilitation. Following a Pre-IND request submitted on March 16, 2021, the FDA agreed with the proposed preclinical efficacy experiments and provided guidance for preclinical safety studies. The Phase 1 clinical trial is slated for Q4 2021 in the UK. Algernon also filed provisional patents for DMT formulations and combination therapies. The company aims to be the first to test DMT in human trials for stroke.

Algernon Pharmaceuticals announced significant results from its Phase 2b/3 COVID-19 trial of NP-120 (Ifenprodil), highlighting a 267 ng/L reduction in interleukin 6 (IL-6) levels in the 20 mg treatment group compared to 7 ng/L in the standard care group (p = 0.0292). This reduction indicates potential therapeutic implications for idiopathic pulmonary fibrosis (IPF) and chronic cough, as the company continues its Phase 2 trial targeting these conditions. Algernon has achieved 50% of its enrollment target for the IPF study, further measuring biomarkers such as C-reactive protein.

Algernon Pharmaceuticals has reached 50% enrollment for its Phase 2 clinical trial of NP-120 (Ifenprodil) targeting idiopathic pulmonary fibrosis (IPF) and chronic cough. The trial aims to evaluate Ifenprodil's efficacy in preserving lung function and reducing cough frequency in IPF patients. In preclinical studies, Ifenprodil demonstrated a 56% reduction in fibrosis and a 42% decrease in cough frequency. The IPF market is projected to grow significantly, from $900 million in 2015 to $3.2 billion by 2025, indicating potential market opportunities for the company.

Algernon Pharmaceuticals Inc. (OTCQB: AGNPF) has filed an end of Phase 2 meeting request with the FDA following the completion of its Phase 2b clinical trial for NP-120 (Ifenprodil) in COVID-19. This meeting aims to discuss clinical trial design and assess the transition to Phase 3 with expedited responses expected due to the pandemic context. The company clarifies it does not claim Ifenprodil can treat or prevent COVID-19. Algernon focuses on repurposing existing drugs for new therapeutic applications.

Algernon Pharmaceuticals Inc. (OTCQB: AGNPF) announced plans to request an End-of-Phase 2 meeting with the FDA following the completion of its Phase 2b COVID-19 trial for NP-120 (Ifenprodil). The company aims to discuss trial data and seek guidance for a potential Phase 3 study. Initial data review has shown some negative dose effects at the 40mg level, with further analysis on key endpoints such as mortality and ICU time planned. Algernon aims to leverage the FDA's feedback to inform their next steps in the development process.

Algernon Pharmaceuticals Inc. (OTCQB: AGNPF) appointed Dr. Steven L. Wolf as a consultant for its clinical research program on AP-188 (DMT) for stroke treatment. Dr. Wolf is a renowned expert in Physical Therapy and Rehabilitation Medicine, with over 300 publications and significant contributions to improving stroke recovery methods. His expertise will guide the design of the Phase 2 clinical study assessing DMT's potential to aid neural recovery post-stroke, following promising results from animal studies. This collaboration may enhance Algernon's research capabilities.

Algernon Pharmaceuticals Inc. (CSE: AGN, OTCQB: AGNPF) announced topline data from its Phase 2b/3 COVID-19 trial of NP-120 (Ifenprodil). Key findings revealed 0% mortality in the 20 mg Ifenprodil group at Day 15 versus 3.3% in the control group. Patients with low blood oxygen showed a return to normal levels more quickly in the treatment group. However, the WHO score showed no significant changes across study arms. The company plans to discuss results with the U.S. FDA and publish detailed data in a peer-reviewed journal.